MCID: INF037
MIFTS: 57

Inflammatory Bowel Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Inflammatory Bowel Disease

MalaCards integrated aliases for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 12 37 29 6 3 15 17
Inflammatory Bowel Diseases 55 44 15 72
Bowel Disease, Inflammatory 40

Classifications:



External Ids:

Disease Ontology 12 DOID:0050589
KEGG 37 H01227
MeSH 44 D015212
NCIt 50 C3138
SNOMED-CT 68 24526004
UMLS 72 C0021390

Summaries for Inflammatory Bowel Disease

KEGG : 37
Inflammatory bowel disease (IBD) is a heterogeneous group of chronic disorders, which includes Crohn's disease and ulcerative colitis. Patients suffer chronically from abdominal pain, diarrhea, bleeding, and malabsorption. In most patients, these disorders are manifested in adolescence or adulthood, however, they may present in infancy and may be inherited as an autosomal recessive trait. It has been reported that mutations in genes encoding the IL10R subunit proteins were found in patients with early-onset enterocolitis, involving hyperinflammatory immune responses in the intestine. Additional genes associated with the disease have been identified.

MalaCards based summary : Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 5 and inflammatory bowel disease 8. An important gene associated with Inflammatory Bowel Disease is CBR3-AS1 (CBR3 Antisense RNA 1), and among its related pathways/superpathways are Antigen processing and presentation and Cytokine-cytokine receptor interaction. The drugs Copper and Clofazimine have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and bone.

Disease Ontology : 12 An intestinal disease characterized by inflammation located in all parts of digestive tract.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

Wikipedia : 75 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.... more...

Related Diseases for Inflammatory Bowel Disease

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 28
Inflammatory Bowel Disease 25 Rare Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1171)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 5 35.8 NOD2 IL23R IBD5
2 inflammatory bowel disease 8 35.7 NOD2 IBD8
3 inflammatory bowel disease 2 35.6 NOD2 IBD2
4 inflammatory bowel disease 20 35.5 NOD2 IBD20
5 inflammatory bowel disease 7 35.5 NOD2 IBD7
6 inflammatory bowel disease 9 35.4 NOD2 IBD9
7 inflammatory bowel disease 3 35.3 NOD2 IBD3
8 inflammatory bowel disease 6 35.0 NOD2 IBD6
9 inflammatory bowel disease 25, autosomal recessive 12.9
10 inflammatory bowel disease 1 12.9
11 inflammatory bowel disease 10 12.9
12 inflammatory bowel disease 17 12.9
13 inflammatory bowel disease 19 12.9
14 inflammatory bowel disease 28, autosomal recessive 12.9
15 inflammatory bowel disease 14 12.8
16 inflammatory bowel disease 13 12.8
17 inflammatory bowel disease 29 12.8
18 inflammatory bowel disease 4 12.8
19 inflammatory bowel disease 16 12.8
20 inflammatory bowel disease 18 12.8
21 inflammatory bowel disease 15 12.8
22 inflammatory bowel disease 24 12.8
23 inflammatory bowel disease 12 12.8
24 inflammatory bowel disease 28 12.8
25 inflammatory bowel disease 21 12.8
26 inflammatory bowel disease 26 12.8
27 inflammatory bowel disease 22 12.7
28 inflammatory bowel disease 23 12.7
29 inflammatory bowel disease 27 12.7
30 inflammatory bowel disease 11 12.7
31 inflammatory bowel disease 25 12.7
32 inflammatory bowel disease, immunodeficiency, and encephalopathy 12.7
33 ulcerative colitis 12.4
34 inflammatory bowel disease-recurrent sinopulmonary infections syndrome 12.3
35 immune dysregulation with inflammatory bowel disease 12.3
36 immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome 12.3
37 rare inflammatory bowel disease 12.3
38 gastrointestinal defects and immunodeficiency syndrome 12.2
39 crohn's disease 12.1
40 cholangitis, primary sclerosing 11.9
41 crohn's colitis 11.8
42 irritable bowel syndrome 11.8
43 spondyloarthropathy 1 11.7
44 ileitis 11.7
45 colitis 11.7
46 ileocolitis 11.7
47 collagenous colitis 11.7
48 immunodeficiency, common variable, 11 11.7
49 glycogen storage disease ib 11.6
50 proctitis 11.6

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease

Symptoms & Phenotypes for Inflammatory Bowel Disease

Drugs & Therapeutics for Inflammatory Bowel Disease

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 496)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Copper Approved, Investigational Phase 4 7440-50-8 27099
2
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
3
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
4
Prucalopride Approved Phase 4 179474-81-8
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Fidaxomicin Approved Phase 4 873857-62-6
8
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
11
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
12
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
13
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
14
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
18
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
19 Orange Approved Phase 4
20
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
23 Strawberry Approved Phase 4
24 Artichoke Approved Phase 4
25
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
26
leucovorin Approved Phase 4 58-05-9 143 6006
27
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
29
carbamide peroxide Approved Phase 4 124-43-6
30
Clarithromycin Approved Phase 4 81103-11-9 84029
31
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
32
Racepinephrine Approved Phase 4 329-65-7 838
33
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
34
Ondansetron Approved Phase 4 99614-02-5 4595
35
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
36
Vancomycin Approved Phase 4 1404-90-6 441141 14969
37
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
38
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
39
Infliximab Approved Phase 4 170277-31-3
40
Ustekinumab Approved, Investigational Phase 4 815610-63-0
41
Zinc oxide Approved Phase 4 1314-13-2
42
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
43
Dalteparin Approved Phase 4 9005-49-6
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
45
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
46
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
47 Rebamipide Investigational Phase 4 90098-04-7
48
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
49 retinol Phase 4
50 Retinol palmitate Phase 4

Interventional clinical trials:

(show top 50) (show all 1361)
# Name Status NCT ID Phase Drugs
1 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
2 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
3 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
4 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
5 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
6 Optimal Substitution Dose of the Vitamin D During Winter Time in Patient With Inflammatory Bowel Diseases (IBD) Unknown status NCT02958501 Phase 4 Colecalciferol
7 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
8 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
9 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
10 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
11 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
12 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
13 EFFICACY, TOLERABILITY, AND SAFETY OF DIFFERENT BOWEL PREPARATIONS FOR COLONOSCOPY IN CHILDREN Unknown status NCT01711437 Phase 4
14 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
15 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
16 Assessment of the Participation Rate and the Diagnostic Accuracy of a Colorectal Cancer Screening Program: CT Colonography Versus Flexible Sigmoidoscopy. Evaluation of a New Model Based on Telediagnosis Unknown status NCT01739608 Phase 4
17 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
18 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
19 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
20 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
21 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
22 A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease Completed NCT02566889 Phase 4 Infliximab
23 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
24 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
25 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
26 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
27 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4 Rosiglitazone
28 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
29 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
30 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
31 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
32 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
33 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
34 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4 Lubiprostone;Placebo
35 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
36 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
37 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
38 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
39 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
40 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
41 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
42 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
43 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
44 Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography Completed NCT02946203 Phase 4
45 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
46 Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease Completed NCT01947010 Phase 4
47 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
48 Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis. Completed NCT01737983 Phase 4
49 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
50 2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial Completed NCT01865916 Phase 4 Polyethylene Glycol (PEG) and 15 mg Bisacodyl;Polyethylene Glycol (PEG) + ascorbic acid

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


clidinium
Clidinium bromide
Cromolyn
Cromolyn Sodium
Technetium Tc-99m exametazime

Cochrane evidence based reviews: inflammatory bowel diseases

Genetic Tests for Inflammatory Bowel Disease

Genetic tests related to Inflammatory Bowel Disease:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 29

Anatomical Context for Inflammatory Bowel Disease

MalaCards organs/tissues related to Inflammatory Bowel Disease:

41
Colon, T Cells, Bone, Liver, Testes, Neutrophil, Small Intestine

The Foundational Model of Anatomy Ontology organs/tissues related to Inflammatory Bowel Disease:

19
All Parts Of Digestive Tract

Publications for Inflammatory Bowel Disease

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 35937)
# Title Authors PMID Year
1
Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. 9 38
19885907 2010
2
Anti-TNF therapy in inflammatory bowel diseases: a huge review. 9 38
20485259 2010
3
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. 9 38
20361960 2010
4
Association analysis of myosin IXB and type 1 diabetes. 9 38
20303373 2010
5
Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement. 9 38
20107854 2010
6
Hydrogen sulfide and substance P in inflammation. 9 38
19803739 2010
7
Association of the interleukin-23 receptor gene variant rs11209026 with Crohn's disease in German children. 9 38
20192940 2010
8
IL-6 may modulate the skeletal response to glucocorticoids during exacerbations of inflammatory bowel disease. 9 38
20229252 2010
9
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. 9 38
20485703 2010
10
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. 9 38
20493732 2010
11
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 9 38
20228197 2010
12
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. 9 38
19710105 2010
13
Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease. 9 38
20184972 2010
14
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. 9 38
20454450 2010
15
The use of GLP-2 and related growth factors in intestinal diseases. 9 38
20336592 2010
16
GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. 9 38
20331905 2010
17
Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. 9 38
20061984 2010
18
Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. 9 38
20138213 2010
19
Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. 9 38
19878610 2010
20
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. 9 38
20210765 2010
21
Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. 9 38
19960028 2010
22
Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. 9 38
20175817 2010
23
Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. 9 38
20446955 2010
24
Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. 9 38
19714744 2010
25
The role of COX-2 in intestinal inflammation and colorectal cancer. 9 38
19946329 2010
26
[Use of TNFalpha antibodies in treatment of inflammatory bowel disease]. 9 38
20160771 2010
27
[Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications]. 9 38
20158097 2010
28
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. 9 38
19808045 2010
29
Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. 9 38
19698701 2010
30
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia. 9 38
20101775 2010
31
Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients. 9 38
20066736 2010
32
Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. 9 38
19724293 2009
33
P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses. 9 38
19890058 2009
34
Actobiotics as a novel method for cytokine delivery. 9 38
20074282 2009
35
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. 9 38
19740775 2009
36
Celiac disease: from pathogenesis to novel therapies. 9 38
19766641 2009
37
Dislocation of Rab13 and vasodilator-stimulated phosphoprotein in inactive colon epithelium in patients with Crohn's disease. 9 38
19885626 2009
38
Evidence for impaired CARD15 signalling in Crohn's disease without disease linked variants. 9 38
19907652 2009
39
Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. 9 38
19908331 2009
40
Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. 9 38
19653082 2009
41
Interleukin-10 in inflammatory bowel disease. 9 38
19890110 2009
42
Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. 9 38
19473188 2009
43
Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. 9 38
19639558 2009
44
Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. 9 38
19575361 2009
45
Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. 9 38
19363798 2009
46
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. 9 38
19839006 2009
47
The role of resistin as a regulator of inflammation: Implications for various human pathologies. 9 38
19740705 2009
48
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? 9 38
19711064 2009
49
PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. 9 38
19462432 2009
50
Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. 9 38
19874614 2009

Variations for Inflammatory Bowel Disease

ClinVar genetic disease variations for Inflammatory Bowel Disease:

6 (show top 50) (show all 85)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 IL10RB NM_000628.5(IL10RB): c.73G> A (p.Glu25Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs80027572 21:34640722-34640722 21:33268417-33268417
2 IL10 NM_000572.3(IL10): c.43G> A (p.Gly15Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs145922845 1:206945738-206945738 1:206772393-206772393
3 IL10RA NM_001558.3(IL10RA): c.144C> T (p.Ile48=) single nucleotide variant Conflicting interpretations of pathogenicity rs140466541 11:117859173-117859173 11:117988458-117988458
4 IL10RA NM_001558.3(IL10RA): c.931T> C (p.Leu311=) single nucleotide variant Conflicting interpretations of pathogenicity rs148808529 11:117869550-117869550 11:117998835-117998835
5 IL10RA NM_001558.3(IL10RA): c.337G> A (p.Val113Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs4252303 11:117860305-117860305 11:117989590-117989590
6 IL10RA NM_001558.3(IL10RA): c.696C> T (p.Thr232=) single nucleotide variant Conflicting interpretations of pathogenicity rs4252311 11:117866311-117866311 11:117995596-117995596
7 IL10RA NM_001558.3(IL10RA): c.706G> A (p.Val236Ile) single nucleotide variant Uncertain significance rs35473928 11:117866321-117866321 11:117995606-117995606
8 IL10RA NM_001558.3(IL10RA): c.*104C> G single nucleotide variant Uncertain significance rs886047710 11:117870460-117870460 11:117999745-117999745
9 IL10RA NM_001558.3(IL10RA): c.*133C> T single nucleotide variant Uncertain significance rs752174 11:117870489-117870489 11:117999774-117999774
10 IL10RA NM_001558.3(IL10RA): c.-54T> C single nucleotide variant Uncertain significance rs886047705 11:117857129-117857129 11:117986414-117986414
11 IL10RA NM_001558.3(IL10RA): c.67+11G> A single nucleotide variant Uncertain significance rs376956484 11:117857260-117857260 11:117986545-117986545
12 IL10RA NM_001558.3(IL10RA): c.67+13G> A single nucleotide variant Uncertain significance rs886047707 11:117857262-117857262 11:117986547-117986547
13 IL10RA NM_001558.3(IL10RA): c.72A> C (p.Thr24=) single nucleotide variant Uncertain significance rs560128585 11:117859101-117859101 11:117988386-117988386
14 IL10RA NM_001558.3(IL10RA): c.320G> A (p.Arg107Gln) single nucleotide variant Uncertain significance rs145949718 11:117860288-117860288 11:117989573-117989573
15 IL10RA NM_001558.3(IL10RA): c.447G> A (p.Lys149=) single nucleotide variant Uncertain significance rs750580462 11:117864035-117864035 11:117993320-117993320
16 IL10RA NM_001558.3(IL10RA): c.*1555C> T single nucleotide variant Uncertain significance rs182393130 11:117871911-117871911 11:118001196-118001196
17 IL10RA NM_001558.3(IL10RA): c.*1664A> G single nucleotide variant Uncertain significance rs886047713 11:117872020-117872020 11:118001305-118001305
18 IL10RA NM_001558.3(IL10RA): c.*1722T> C single nucleotide variant Uncertain significance rs886047714 11:117872078-117872078 11:118001363-118001363
19 IL10RA NM_001558.3(IL10RA): c.25C> T (p.Leu9=) single nucleotide variant Uncertain significance rs886047706 11:117857207-117857207 11:117986492-117986492
20 IL10RA NM_001558.3(IL10RA): c.80C> T (p.Pro27Leu) single nucleotide variant Uncertain significance rs755758777 11:117859109-117859109 11:117988394-117988394
21 IL10RA NM_001558.3(IL10RA): c.*676C> T single nucleotide variant Uncertain significance rs756303257 11:117871032-117871032 11:118000317-118000317
22 IL10RA NM_001558.3(IL10RA): c.*854C> G single nucleotide variant Uncertain significance rs535662153 11:117871210-117871210 11:118000495-118000495
23 IL10RA NM_001558.3(IL10RA): c.188+3G> A single nucleotide variant Uncertain significance rs780334422 11:117859220-117859220 11:117988505-117988505
24 IL10RA NM_001558.3(IL10RA): c.336C> T (p.Thr112=) single nucleotide variant Uncertain significance rs192749274 11:117860304-117860304 11:117989589-117989589
25 IL10RA NM_001558.3(IL10RA): c.1188G> A (p.Arg396=) single nucleotide variant Uncertain significance rs35465632 11:117869807-117869807 11:117999092-117999092
26 IL10RA NM_001558.3(IL10RA): c.*756T> C single nucleotide variant Uncertain significance rs188436763 11:117871112-117871112 11:118000397-118000397
27 IL10RA NM_001558.3(IL10RA): c.*968G> A single nucleotide variant Uncertain significance rs562515149 11:117871324-117871324 11:118000609-118000609
28 IL10RA NM_001558.3(IL10RA): c.*1684G> A single nucleotide variant Uncertain significance rs143719655 11:117872040-117872040 11:118001325-118001325
29 IL10RB NM_000628.5(IL10RB): c.-72C> A single nucleotide variant Uncertain significance rs45607743 21:34638699-34638699 21:33266394-33266394
30 IL10RB NM_000628.5(IL10RB): c.727G> A (p.Ala243Thr) single nucleotide variant Uncertain significance rs1058861 21:34660489-34660489 21:33288184-33288184
31 IL10RB NM_000628.5(IL10RB): c.*515C> T single nucleotide variant Uncertain significance rs767017864 21:34669177-34669177 21:33296872-33296872
32 IL10RB NM_000628.5(IL10RB): c.*616A> G single nucleotide variant Uncertain significance rs886057009 21:34669278-34669278 21:33296973-33296973
33 IL10RA NM_001558.3(IL10RA): c.-70C> T single nucleotide variant Uncertain significance rs185159635 11:117857113-117857113 11:117986398-117986398
34 IL10RB NM_000628.5(IL10RB): c.*761C> T single nucleotide variant Uncertain significance rs567397652 21:34669423-34669423 21:33297118-33297118
35 IL10RB NM_000628.5(IL10RB): c.*616del deletion Uncertain significance rs5843596 21:34669278-34669278 21:33296973-33296973
36 IL10RB NM_000628.5(IL10RB): c.*593_*594TC[1] short repeat Uncertain significance rs886057007 21:34669257-34669258 21:33296952-33296953
37 IL10RA NM_001558.3(IL10RA): c.785G> A (p.Arg262His) single nucleotide variant Uncertain significance rs202121581 11:117866400-117866400 11:117995685-117995685
38 IL10RA NM_001558.3(IL10RA): c.810+10G> A single nucleotide variant Uncertain significance rs12290349 11:117866435-117866435 11:117995720-117995720
39 IL10RA NM_001558.3(IL10RA): c.781C> T (p.Arg261Trp) single nucleotide variant Uncertain significance rs201396764 11:117866396-117866396 11:117995681-117995681
40 IL10RA NM_001558.3(IL10RA): c.1323G> A (p.Val441=) single nucleotide variant Uncertain significance rs746663189 11:117869942-117869942 11:117999227-117999227
41 IL10RA NM_001558.3(IL10RA): c.*1352G> A single nucleotide variant Uncertain significance rs570165681 11:117871708-117871708 11:118000993-118000993
42 IL10RA NM_001558.3(IL10RA): c.67+15C> T single nucleotide variant Uncertain significance rs886047708 11:117857264-117857264 11:117986549-117986549
43 IL10RA NM_001558.3(IL10RA): c.*1375C> A single nucleotide variant Uncertain significance rs141609122 11:117871731-117871731 11:118001016-118001016
44 IL10RA NM_001558.3(IL10RA): c.96G> A (p.Val32=) single nucleotide variant Uncertain significance rs377525753 11:117859125-117859125 11:117988410-117988410
45 IL10RA NM_001558.3(IL10RA): c.*639C> T single nucleotide variant Uncertain significance rs562410825 11:117870995-117870995 11:118000280-118000280
46 IL10RA NM_001558.3(IL10RA): c.*863C> T single nucleotide variant Uncertain significance rs779722798 11:117871219-117871219 11:118000504-118000504
47 IL10RA NM_001558.3(IL10RA): c.*866C> A single nucleotide variant Uncertain significance rs145605428 11:117871222-117871222 11:118000507-118000507
48 IL10RA NM_001558.3(IL10RA): c.*1058A> G single nucleotide variant Uncertain significance rs886047712 11:117871414-117871414 11:118000699-118000699
49 IL10RA NM_001558.3(IL10RA): c.1281C> T (p.Pro427=) single nucleotide variant Uncertain significance rs767275130 11:117869900-117869900 11:117999185-117999185
50 IL10RA NM_001558.3(IL10RA): c.1452G> A (p.Glu484=) single nucleotide variant Uncertain significance rs139576148 11:117870071-117870071 11:117999356-117999356

Expression for Inflammatory Bowel Disease

Search GEO for disease gene expression data for Inflammatory Bowel Disease.

Pathways for Inflammatory Bowel Disease

Pathways related to Inflammatory Bowel Disease according to KEGG:

37
# Name Kegg Source Accession
1 Antigen processing and presentation hsa04612
2 Cytokine-cytokine receptor interaction hsa04060
3 JAK-STAT signaling pathway hsa04630
4 Inflammatory bowel disease (IBD) hsa05321
5 Autophagy - animal hsa04140

GO Terms for Inflammatory Bowel Disease

Biological processes related to Inflammatory Bowel Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of interleukin-17 production GO:0032740 8.62 NOD2 IL23R

Sources for Inflammatory Bowel Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....